Additionally, scientists at Xuzhou Medical University developed bispecific CAR T cells targeting CD19 and BCMA to reset immune responses in relapsed or treatment-resistant Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), resulting in improved muscle function and reduced disability (19). Here, CD19 is linked to chronic inflammatory demyelinating polyradiculoneuropathy.